Unlock instant, AI-driven research and patent intelligence for your innovation.

Crystalline state Lesinurad intermediate and preparation method thereof

A crystal form and intermediate technology, applied in the field of medicine, can solve the problems of difficult purification of the final product Lesinurad, many steps, cumbersome operation, etc., and achieve the effects of convenient storage and transportation, subsequent feeding operation, stable properties, and simple operation

Inactive Publication Date: 2017-11-07
CSPC ZHONGQI PHARM TECH (SHIJIAZHUANG) CO LTD
View PDF11 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

If the intermediate II is not purified, further alkali is added for deesterification reaction to generate Lesinurad, and the intermediate II impurities with different brominated or polybrominated substitutions also undergo deesterification reaction to generate brominated Lesinurad impurities. Due to the properties of brominated impurities Similar to the product Lesinurad, it is not easy to separate and remove, which brings great difficulties to the purification of the final product Lesinurad
For example, in Example 2A of WO2014008295, the preparation of Lesinurad is to post-process the prepared intermediate II and generate Lesinurad sodium salt through deesterification, then acidify it with HBr acid, and then extract it with ethyl acetate multiple times, and then It is obtained by concentrating ethyl acetate to a certain volume and crystallizing it by adding n-heptane. There are many steps and cumbersome operation
[0024] In summary, the prior art does not obtain high-purity, crystalline Lesinurad intermediate II, nor discloses a purification method for Lesinurad intermediate II suitable for industrial production

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Crystalline state Lesinurad intermediate and preparation method thereof
  • Crystalline state Lesinurad intermediate and preparation method thereof
  • Crystalline state Lesinurad intermediate and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0068] Embodiment 1: the preparation of Lesinurad intermediate II crystal

[0069] In a 100mL three-neck flask, add 10g of crude Lesinurad intermediate II (23.9mmol) and 30mL of N,N-dimethylformamide, stir at room temperature to dissolve, then add 14.5mL of 3N hydrochloric acid (43.5mmol), there are a lot of solids during stirring Precipitate, then add 200mL acetone. Cool down to 0°C and continue stirring for 1h. Suction filtration, wash the filter cake with acetone, and vacuum dry to obtain 9.35g of white solid, the yield is 93.5%, and the HPLC purity is 98.8%. The obtained solid sample is subjected to powder X-ray powder diffraction, and the detection result is a crystalline solid. The obtained spectrum is shown in attached figure 1 , and the spectral data are shown in Table 1.

[0070] Table 1 embodiment 1 gained Lesinurad intermediate II crystalline powder X-ray diffraction characteristic peak data

[0071]

[0072]

[0073] The resulting crystalline sample was ...

Embodiment 2

[0074] Embodiment 2: the preparation of Lesinurad intermediate II crystal

[0075] Add 10g of crude Lesinurad intermediate II (23.9mmol) and 50mL of ethanol to a 100mL three-necked flask, heat to 30°C, stir to dissolve, then add 3.8mL of acetic acid (66.3mmol), a large amount of solids precipitate out during stirring, then add 150mL of isopropyl Alcohol, cooled to 0 ℃, continue to stir for 2h. Suction filtration, the filter cake was washed with isopropanol, and vacuum-dried to obtain 9.09 g of white solid, the yield was 90.9%, and the HPLC purity was 98.2%. The obtained solid sample was subjected to powder X-ray powder diffraction, and the detection result was a crystalline solid. The obtained See attached figure 2 , and the spectral data are shown in Table 2.

[0076] Table 2 embodiment 2 gained Lesinurad intermediate II crystalline powder X-ray diffraction characteristic peak data

[0077]

[0078]

[0079] The resulting crystalline sample was subjected to differen...

Embodiment 3

[0080] Embodiment 3: the preparation of Lesinurad intermediate II crystal

[0081] Add 10g of crude Lesinurad intermediate II (23.9mmol) and 200mL of acetonitrile to a 500mL three-necked flask, heat to 30°C, stir to dissolve, then add 23.9mL of 2N sulfuric acid (47.8mmol), a large amount of solids precipitate out during stirring, cool down to 0°C , continue to stir for 2h. Suction filtration, wash the filter cake with acetonitrile, and vacuum dry to obtain 8.86g of white solid, the yield is 88.6%, and the HPLC purity is 98.6%. The obtained solid sample is subjected to powder X-ray powder diffraction, and the detection result is a crystalline solid. The obtained spectrum is shown in attached image 3 , and the spectral data are shown in Table 3.

[0082] Table 3 embodiment 3 gained Lesinurad intermediate II crystalline powder X-ray diffraction characteristic peak data

[0083]

[0084]

[0085] The resulting crystalline sample was subjected to differential scanning calor...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a crystalline state Lesinurad intermediate and a preparation method thereof. The invention discloses a crystalline state Lesinurad intermediate (II) and a preparation method thereof. The result of differential scanning calorimetry on the crystalline state Lesinurad intermediate (II) shows that peaks appear in a range of 98 to 102 DEG C. The result of powder X-ray diffraction shows that characteristic peaks appear at (2[theta]): 8.8+ / -0.2 degrees, 10.5+ / -0.2 degrees, 10.6+ / -0.2 degrees, 15.6+ / -0.2 degrees, 22.1+ / -0.2 degrees, and 22.9+ / -0.2 degrees. The solid of crystalline state Lesinurad intermediate (II) is obtained for the first time, the purity is high, the operation of the crystallization method is simple, column chromatography purification is not needed, the method is suitable for industrial production; the obtained crystalline state solid has stable properties, thus storage, transportation, and feeding operation become convenient, and the purity of final product Lesinurad prepared from the intermediate (II) is high.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a crystalline Lesinurad intermediate and a preparation method thereof. Background technique [0002] Gout is a crystal-associated arthropathy caused by deposition of monosodium urate, and is a worldwide prevalent metabolic disease. The prevalence of gout in my country is about 0.15% to 0.67%. With the rapid development of the economy, people's intake of high-protein foods continues to increase, and the prevalence of gout and hyperuricemia is also increasing. [0003] Lesinurad (structural formula shown in formula I), chemical name is 2-[[5-bromo-4-(4-cyclopropyl-1-naphthalene-1-yl)-4H-1,2,4-triazole- 3-yl]thio]acetic acid, a uric acid transporter 1 (URAT1) inhibitor developed by AstraZeneca, was approved for marketing in the United States in 2015, under the trade name ZURAMPIC, for use in combination with xanthine oxidase inhibitors (XOLs) for the treatment of gou...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D249/12
CPCC07B2200/13C07D249/12
Inventor 龚登凰王洁杨杰盖京华杨敏杨春巧马玉秀
Owner CSPC ZHONGQI PHARM TECH (SHIJIAZHUANG) CO LTD